Literature DB >> 7764454

Topoisomerase I in multiple drug resistance.

A Pessina1.   

Abstract

Topoisomerase I is a nuclear enzyme able to catalyse the relaxation of supercoiled DNA by introducing single-stranded breaks in DNA molecule. Its function seems important to prepare DNA for many processes such as recombination, DNA repair and RNA transcription. The most important drugs active as inhibitors of topoisomerase I are represented by camptothecin and its derivatives which were developed as promising anticancer drugs. Since selectivity of action is essential for an antitumor drug, many studies were performed to investigate the mechanisms by which cancer cells become resistant to drug treatment by developing a condition of multiple drug resistance (MDR). This article analyses the role of topoisomerase I in cell functions, considers the cellular effects of topo I poisons and discusses the ways by which tumoral cells may become resistant to these drugs with a special attention to MDR mechanisms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7764454     DOI: 10.1007/BF00744661

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  64 in total

Review 1.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

Review 2.  Topoisomerase-targeting antitumor drugs.

Authors:  P D'Arpa; L F Liu
Journal:  Biochim Biophys Acta       Date:  1989-12-17

3.  Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.

Authors:  H Zhang; J C Wang; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

4.  Characterization of a camptothecin-resistant human DNA topoisomerase I in an in vitro system for Simian virus 40 DNA replication.

Authors:  Y Ishimi; M Nishizawa; T Andoh
Journal:  Eur J Biochem       Date:  1991-12-18

Review 5.  The cell biology of multiple drug resistance.

Authors:  W T Beck
Journal:  Biochem Pharmacol       Date:  1987-09-15       Impact factor: 5.858

6.  Mechanism of inhibition of mammalian DNA topoisomerase I by heparin.

Authors:  K Ishii; S Futaki; H Uchiyama; K Nagasawa; T Andoh
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

7.  Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.

Authors:  B C Baguley; K M Holdaway; L M Fray
Journal:  J Natl Cancer Inst       Date:  1990-03-07       Impact factor: 13.506

8.  Characterization of a camptothecin-resistant human DNA topoisomerase I.

Authors:  E Kjeldsen; B J Bonven; T Andoh; K Ishii; K Okada; L Bolund; O Westergaard
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

9.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

10.  Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines.

Authors:  K Snow; W Judd
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more
  4 in total

1.  Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.

Authors:  Jean-François Marquis; Isabelle Hardy; Martin Olivier
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Label-free recognition of drug resistance via impedimetric screening of breast cancer cells.

Authors:  Bilge Eker; Robert Meissner; Arnaud Bertsch; Kapil Mehta; Philippe Renaud
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

4.  Ependymomas overexpress chemoresistance and DNA repair-related proteins.

Authors:  Sherise D Ferguson; Shouhao Zhou; Joanne Xiu; Yuuri Hashimoto; Nader Sanai; Lyndon Kim; Santosh Kesari; John de Groot; David Spetzler; Amy B Heimberger
Journal:  Oncotarget       Date:  2017-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.